title: Sustained immunological responses to highly active antiretroviral therapy at 36 months in a Ghanaian HIV cohort.
abstract: Two hundred thirty-seven Ghanaian human immunodeficiency virus-infected patients who were starting antiretroviral therapy underwent clinical and immunological monitoring for 3 years. Seventy-eight percent of patients had disease classified as World Health Organization stage III or IV. The mean increase in the CD4 cell count was 395 cells/mm(3), 13% of patients experienced immunological failure, and 8% of patients switched treatment to a second-line regimen. However, two-thirds of patients who experienced immunological failure did not switch treatment, and 31% of all patients were lost to follow-up.
authors.affiliation: School of Medicine and Biomedical Sciences, University of Sheffield, Sheffield, United Kingdom. P.Collini@sheffield.ac.uk
authors.forename: Paul
authors.initials: P
authors.lastname: Collini
authors.forename: Uli
authors.initials: U
authors.lastname: Schwab
authors.forename: Stephen
authors.initials: S
authors.lastname: Sarfo
authors.forename: Joseph
authors.initials: J
authors.lastname: Obeng-Baah
authors.forename: Betty
authors.initials: B
authors.lastname: Norman
authors.forename: David
authors.initials: D
authors.lastname: Chadwick
authors.forename: David
authors.initials: D
authors.lastname: Bibby
authors.forename: George
authors.initials: G
authors.lastname: Bedu-Addo
mesh_terms: D000293:Adolescent; D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D018791:CD4 Lymphocyte Count; D005260:Female; D005869:Ghana; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D019380:Anti-HIV Agents